226 related articles for article (PubMed ID: 34795307)
1. Evaluation of PD-L1 and tumor infiltrating lymphocytes in paired pretreatment biopsies and post neoadjuvant chemotherapy surgical specimens of breast carcinoma.
Hoffmann LG; Sarian LO; Vassallo J; de Paiva Silva GR; Ramalho SOB; Ferracini AC; da Silva Araujo K; Jales RM; Figueira DE; Derchain S
Sci Rep; 2021 Nov; 11(1):22478. PubMed ID: 34795307
[TBL] [Abstract][Full Text] [Related]
2. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
Sarradin V; Lusque A; Filleron T; Dalenc F; Franchet C
Breast Cancer Res; 2021 May; 23(1):61. PubMed ID: 34039396
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
[TBL] [Abstract][Full Text] [Related]
4. Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression.
Brcic I; Kluba AM; Godschachner TM; Suppan C; Regitnig P; Dandachi N; Lax SF; Balić M
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614261
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
[TBL] [Abstract][Full Text] [Related]
6. The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy.
Waks AG; Stover DG; Guerriero JL; Dillon D; Barry WT; Gjini E; Hartl C; Lo W; Savoie J; Brock J; Wesolowski R; Li Z; Damicis A; Philips AV; Wu Y; Yang F; Sullivan A; Danaher P; Brauer HA; Osmani W; Lipschitz M; Hoadley KA; Goldberg M; Perou CM; Rodig S; Winer EP; Krop IE; Mittendorf EA; Tolaney SM
Clin Cancer Res; 2019 Aug; 25(15):4644-4655. PubMed ID: 31061067
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.
Hou Y; Nitta H; Wei L; Banks PM; Parwani AV; Li Z
Clin Breast Cancer; 2018 Apr; 18(2):e237-e244. PubMed ID: 29198959
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components.
Lien HC; Lee YH; Chen IC; Lin CH; Chen TW; Lu YT; Lu YS
Virchows Arch; 2021 Apr; 478(4):669-678. PubMed ID: 33089401
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
10. [Correlation analysis of PD-L1 expression and prognosis in triple-negative breast cancers].
Pan BJ; Xu C; Ping GQ; Song GX; Zhang WM; Wang C; Zhang ZH
Zhonghua Bing Li Xue Za Zhi; 2017 Dec; 46(12):822-826. PubMed ID: 29224274
[No Abstract] [Full Text] [Related]
11. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
Van Berckelaer C; Rypens C; van Dam P; Pouillon L; Parizel M; Schats KA; Kockx M; Tjalma WAA; Vermeulen P; van Laere S; Bertucci F; Colpaert C; Dirix L
Breast Cancer Res; 2019 Feb; 21(1):28. PubMed ID: 30777104
[TBL] [Abstract][Full Text] [Related]
12. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
13. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.
Pelekanou V; Barlow WE; Nahleh ZA; Wasserman B; Lo YC; von Wahlde MK; Hayes D; Hortobagyi GN; Gralow J; Tripathy D; Porter P; Szekely B; Hatzis C; Rimm DL; Pusztai L
Mol Cancer Ther; 2018 Jun; 17(6):1324-1331. PubMed ID: 29588392
[TBL] [Abstract][Full Text] [Related]
15. [PD-L1 status in breast cancer].
Frank GA; Kuznetsova OA; Zavalishina LE; Andreeva YY; Olyushina EM; Vinogradov IY; Vinogradov MI; Kulikov EP; Shomova MV
Arkh Patol; 2019; 81(2):3-9. PubMed ID: 31006773
[TBL] [Abstract][Full Text] [Related]
16. A Potential Predictive Biomarker for Miller/Payne Grading: PD-L1 Expression before Neoadjuvant Chemotherapy in Breast Cancer.
Li C; Ma RZ; Han GY; Guo YH; Zhang YN; Zhang YT; Wang H; Zhang YP; Chen FM; Zhang SG; Wang MC; Hao FR; Zhang YX
Oncol Res Treat; 2020; 43(11):573-583. PubMed ID: 32957100
[TBL] [Abstract][Full Text] [Related]
17. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
[TBL] [Abstract][Full Text] [Related]
18. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
19. An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer.
McLemore LE; Janakiram M; Albanese J; Shapiro N; Lo Y; Zang X; Fineberg S
Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):611-619. PubMed ID: 28422766
[TBL] [Abstract][Full Text] [Related]
20. Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer.
Sanchez K; Kim I; Chun B; Pucilowska J; Redmond WL; Urba WJ; Martel M; Wu Y; Campbell M; Sun Z; Grunkemeier G; Chang SC; Bernard B; Page DB
Breast Cancer Res; 2021 Jan; 23(1):2. PubMed ID: 33413574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]